VentriPoint adds Mayo Clinic to clinical trial
Article Thumbnail ImageJune 14, 2012 -- Echocardiography technology developer VentriPoint said that the Mayo Clinic will participate in a multicenter clinical trial to evaluate the firm's VMS ultrasound diagnostic tool in patients with pulmonary arterial hypertension (PAH).
Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Sign in using your social networking account:
Sign in using your social networking

The company said it's currently pursuing U.S. Food and Drug Administration (FDA) 510(k) clearance for VMS. The tool is cleared for sale and clinical use in Canada and Europe, VentriPoint said.